Semax
🔹 What is Semax?
Class: Synthetic heptapeptide; analog of adrenocorticotropic hormone (ACTH) fragment 4–10. Mechanism:
- Enhances BDNF expression, supporting neuroplasticity, learning, and memory.
- Modulates dopamine and serotonin signaling, improving focus, alertness, and mood.
- Exhibits neuroprotective and antioxidant properties, reducing neuronal damage from ischemia or oxidative stress.
- Activates cognitive resilience pathways, including anti-inflammatory and mitochondrial support mechanisms.
- Rapid onset via intranasal delivery; crosses blood–brain barrier efficiently.
Primary focus:
- Cognitive enhancement (focus, memory, learning).
- Neuroprotection in ischemic, oxidative, or stress-related injury.
- Mood stabilization and stress resilience.
- Potential anti-aging brain support and recovery from cognitive fatigue.
- Additional research applications noted in the literature: reduced tumor size in an experimental breast cancer model, used as an anti-ulcer treatment (accelerates gastric ulcer healing and improves blood/lymphatic supply to gastric mucosa), promotes neuron survival during hypoxia and glutamate neurotoxicity, and influences vascular-system gene expression relevant to brain ischemia recovery.
🔹 Oral Dosage
- Poor oral bioavailability; oral use is rare and largely experimental.
- Sublingual forms exist in research but dosing data is minimal.
🔹 Injectable / Nasal Dosage (most common) Range:
- 250–1000 µg intranasal, 1–3x daily depending on cognitive demand or stress level.
- SC or IV injections are less common; intranasal route preferred for direct CNS delivery.
Typical research protocol:
- 500 µg intranasal, 2–3x/day for 2–4 weeks.
- Broader dosing reference: 750–1,000 mcg intranasally, or 100–300 mcg SubQ daily. Doses above this range risk receptor desensitization.
Rationale: Direct nose-to-brain delivery maximizes CNS penetration and onset of cognitive effects. Because Semax and Selank share the Pro-Gly-Pro sequence motif, the two are sometimes alternated with each other depending on individual response.
Real-world compounded example: Semax 7,500 mcg/ml (6 ml nasal spray bottle) — dosed at 1–2 sprays intranasally daily or as needed, for neurological function and anxiety support.
🔹 Cycle Length
- Short-term cognitive boost or stress adaptation: 2–4 weeks.
- Extended neuroprotective support: 6–12 weeks, with breaks to avoid receptor desensitization.
🔹 Optimal Dosing Window
- Morning and early afternoon → supports alertness and focus during the day.
- Can be split into 2–3 doses depending on cognitive load.
- Avoid late-evening dosing in sensitive individuals (may interfere with sleep).
✅ Educational Integration Example Example protocol: 500 µg intranasal, morning + early afternoon, for 6 weeks. Paired with: Selank 500 µg intranasal, 1–2x/day + Lion’s Mane + NAD⁺ 100 mg SC 2–3x/week. Rationale: Enhances neuroplasticity and mood balance while supporting mitochondrial function and cognitive endurance.
🔹 Stacking Strategy (Educational / Complementary) Since Semax targets BDNF pathways, cognitive resilience, and neuroprotection, stacks emphasize stress balance, plasticity, and mitochondrial support: 🔸 Neuroplasticity & Cognitive Enhancement
- Selank → anxiolysis and neurotransmitter stabilization, complements Semax’s focus-enhancing effects.
- Dihexa → synaptogenesis and deep neuroplasticity support.
- P021 / PE-22-28 → additional neurotrophic and structural support.
🔸 Mitochondrial & Energy Support
- NAD⁺ / NMN / NR → sustain neuronal energy and repair.
- MOTS-c / SS-31 → protect mitochondria, synergizing with Semax-mediated cognitive support.
🔸 Mood & Stress Regulation
- Lion’s Mane → supports NGF-driven repair.
- Low-dose adaptogens (Ashwagandha, Rhodiola) → complement stress resilience pathways.
Rationale: Semax forms the foundation for neuroplasticity and focus, while stacks add anxiolytic, mitochondrial, and structural support.
⚠️ Safety Notes
- Well tolerated; mild side effects include nasal irritation, transient headache, or mild fatigue.
- Non-addictive and generally safe in preclinical and limited clinical studies.
- Long-term human safety data is limited; most research is from Russia/Eastern Europe.
Studied in Humans? Yes
FDA Approved? No
Allowed for 503a Compounding Pharmacy? No
Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.